RT Journal Article
SR Electronic
T1 Cyclooxygenase 2 Expression in Soft Tissue Leiomyosarcoma
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 2913
OP 2917
VO 29
IS 8
A1 MEGAN E. HERCEG
A1 ATHANASIOS C. TSIATIS
A1 JENNIFER L. HALPERN
A1 GINGER E. HOLT
A1 HERBERT S. SCHWARTZ
A1 VICKI L. KEEDY
A1 JUSTIN M.M. CATES
YR 2009
UL http://ar.iiarjournals.org/content/29/8/2913.abstract
AB Background: Cyclooxygenase 2 (COX2) expression is up-regulated and associated with adverse prognosis in select types of carcinoma. Although not extensively studied in skeletal or soft tissue sarcoma, expression of COX2 has been described in a variable number of gynecological and non-gynecological leiomyosarcomas. In this study, the prevalence and prognostic implications of COX2 expression in leiomyosarcoma were evaluated further. Materials and Methods: Immunohistochemical stains for COX2 were performed on 33 samples of soft tissue leiomyosarcoma and tested for their association with clinicopathological parameters and patient outcome. Results: COX2 staining was limited to tumor cells surrounding areas of tumor necrosis in 6 cases. There were no statistically significant correlations with the clinicopathological parameters studied, including local recurrence, distant metastasis, or disease-specific death. Conclusion: The low frequency, restricted distribution and absence of prognostic implications of COX2 expression soft tissue leiomyosarcoma suggest that this enzyme may not be a useful pharmacological target in this clinical setting.